⦿ Executive Snapshot

• What: Zealand Pharma announced its financial results for Q1 2026, highlighting advancements in its obesity drug pipeline and financial strategies.
• Who: Zealand Pharma A/S, Boehringer Ingelheim, Roche, Adam Steensberg (CEO).
• Why it matters: The developments in obesity treatments and the establishment of a new research hub signal Zealand Pharma's commitment to innovation in metabolic health, potentially reshaping treatment options in the sector.

⦿ Key Developments

• Zealand Pharma will advance petrelintide into Phase 3 trials in H2 2026 after promising results from the Phase 2 ZUPREME-1 trial, indicating significant weight loss potential.
• Boehringer Ingelheim reported positive topline results from the SYNCHRONIZETM-1 Phase 3 trial with survodutide, showing it as a viable treatment for obesity.
• Zealand Pharma initiated a USD 200 million share buy-back program, reflecting a robust financial outlook linked to progress in obesity therapies.
• The company established a new research hub in Cambridge, Massachusetts, enhancing its capabilities in drug discovery through AI partnerships.
• Zealand Pharma's revenue for Q1 2026 was reported at DKK 34 million, significantly up from DKK 8 million in Q1 2025, indicating strong financial growth.

⦿ Strategic Context

• Zealand Pharma's focus on obesity treatments fits into a broader market trend of increasing demand for effective weight management solutions as obesity rates rise globally.
• The establishment of advanced research facilities and partnerships positions Zealand Pharma to leverage cutting-edge technologies, such as AI, for drug discovery, aligning with industry shifts towards innovation-driven healthcare solutions.

⦿ Strategic Implications

• The advancements in clinical trials for petrelintide and survodutide may enhance Zealand Pharma's competitive positioning in the obesity treatment market, potentially leading to increased market share.
• The financial strategies, including the share buy-back program, could improve investor confidence and support long-term investments in R&D, fueling future growth.

⦿ Risks & Constraints

• Regulatory hurdles and the need for successful clinical trial outcomes pose significant risks to the advancement of petrelintide and survodutide.
• Competition from other biotechnology firms developing obesity treatments may impact Zealand Pharma's market penetration and profitability.

⦿ Watchlist / Forward Signals

• Key upcoming events include the initiation of Phase 3 trials for petrelintide and the presentation of additional data at the American Diabetes Association’s 2026 Scientific Session.
• The success of the share buy-back program and the financial performance in subsequent quarters will be crucial indicators of Zealand Pharma's operational health and market strategy effectiveness.